The Challenge of Personalized Nutrition for Multiple Sclerosis: Laura Piccio, MD, PhD

Published Date: 02 Mar 2023

The Challenge of Personalized Nutrition for Multiple Sclerosis: Laura Piccio, MD, PhD

Read Full News

Latest News

New Phase 2 Trial to Test TREM2-Stabilizing Agent VHB937 in Alzheimer Disease Marco Meglio

A phase 2 study at CTAD 2025 explores VHB937's potential in treating early Alzheimer disease, focusing on safety and efficacy in patients.

Phase 3 Trial to Uncover Therapeutic Potential of 5-HT6 Antagonist Masupirdine to Treat Alzheimer Agitation Louie Pasculli

A new phase 3 clinical trial is underway to evaluate masupirdine, a selective 5-HT6 receptor antagonist, as a potential treatment for agitation in patients with Alzheimer’s disease.

MRI Analysis Shows Stem Cell Therapy Laromestrocel Reduced Neuroinflammation in Mild Alzheimer Disease Isabella Ciccone, MPH

In an analysis of the phase 2a CLEAR MIND study presented at CTAD 2025, laromestrocel treatment was associated with reduced hippocampal neuroinflammation in patients with mild Alzheimer disease.

This Week on NeurologyLive® — December 1, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

NeurologyLive® Brain Games: November 30, 2025 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on Phosphorylated tau 181!

Early Phase 3 Data Highlight Convenience and Feasibility of Self-Administered Alzheimer Agent Remternetug Marco Meglio

New findings reveal the feasibility of self-administering remternetug, a monoclonal antibody for Alzheimer’s, enhancing treatment options for early-stage patients.

Todays Updates

LEVI-04 Improves Pain, Function in Knee Osteoarthritis, with Philip Conaghan, MBBS, PhD Philip Conaghan, MBBS, PhD

Conaghan discussed the potential of LEVI-04 for knee osteoarthritis at ACR 2025.

Alzheimer Trial PRImus-AD Tests Orally Available PRI-002 as New Treatment Louie Pasculli

The adaptive PRImus-AD phase 2a trial will evaluate the safety and efficacy of PRI-002, a novel investigational agent, in patients with mild cognitive impairment or mild Alzheimer disease.

CTAD Poster Shows Etalanetug Reduced Tau Pathology Biomarkers in Dominantly Inherited Alzheimer Disease Isabella Ciccone, MPH

Treatment with etalanetug reduced cerebrospinal fluid eMTBR-tau243 by 62% and plasma eMTBR-tau243 by 78% at 3 months in patients with dominantly inherited Alzheimer disease.

Alzheimer Vaccine ABvac40 Results in Lowered Cortical Perfusion Decline Marco Meglio

A recent study reveals that Araclon's ABvac40 vaccine may slow cortical perfusion decline in patients with Alzheimer disease, suggesting potential cognitive benefits.

Difficult Cases and Red Flags in Dermatology, With Kassandra Holzem, MD Kassandra Holzem, MD

In her SDPA Fall Dermatology Conference interview, Holzem highlights key warning signs for a variety of dermatologic conditions requiring hospital admission.

Firsekibart Beats Colchicine as Gout Flare Prophylaxis When Initiating ULT

Firsekibart Beats Colchicine as Gout Flare Prophylaxis When Initiating ULT

Deep Capillary Plexus Microaneurysms A Sign of CKD in Diabetic Retinopathy

Deep Capillary Plexus Microaneurysms A Sign of CKD in Diabetic Retinopathy

Todays Updates

LEVI-04 Improves Pain, Function in Knee Osteoarthritis, with Philip Conaghan, MBBS, PhD Philip Conaghan, MBBS, PhD

Conaghan discussed the potential of LEVI-04 for knee osteoarthritis at ACR 2025.

Alzheimer Trial PRImus-AD Tests Orally Available PRI-002 as New Treatment Louie Pasculli

The adaptive PRImus-AD phase 2a trial will evaluate the safety and efficacy of PRI-002, a novel investigational agent, in patients with mild cognitive impairment or mild Alzheimer disease.

CTAD Poster Shows Etalanetug Reduced Tau Pathology Biomarkers in Dominantly Inherited Alzheimer Disease Isabella Ciccone, MPH

Treatment with etalanetug reduced cerebrospinal fluid eMTBR-tau243 by 62% and plasma eMTBR-tau243 by 78% at 3 months in patients with dominantly inherited Alzheimer disease.

Alzheimer Vaccine ABvac40 Results in Lowered Cortical Perfusion Decline Marco Meglio

A recent study reveals that Araclon's ABvac40 vaccine may slow cortical perfusion decline in patients with Alzheimer disease, suggesting potential cognitive benefits.

Difficult Cases and Red Flags in Dermatology, With Kassandra Holzem, MD Kassandra Holzem, MD

In her SDPA Fall Dermatology Conference interview, Holzem highlights key warning signs for a variety of dermatologic conditions requiring hospital admission.

Firsekibart Beats Colchicine as Gout Flare Prophylaxis When Initiating ULT

Firsekibart Beats Colchicine as Gout Flare Prophylaxis When Initiating ULT

Deep Capillary Plexus Microaneurysms A Sign of CKD in Diabetic Retinopathy

Deep Capillary Plexus Microaneurysms A Sign of CKD in Diabetic Retinopathy

Latest News

A phase 2 study at CTAD 2025 explores VHB937's potential in treating early Alzheimer disease, focusing on safety and efficacy in patients.

A new phase 3 clinical trial is underway to evaluate masupirdine, a selective 5-HT6 receptor antagonist, as a potential treatment for agitation in patients with Alzheimer’s disease.

In an analysis of the phase 2a CLEAR MIND study presented at CTAD 2025, laromestrocel treatment was associated with reduced hippocampal neuroinflammation in patients with mild Alzheimer disease.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on Phosphorylated tau 181!

New findings reveal the feasibility of self-administering remternetug, a monoclonal antibody for Alzheimer’s, enhancing treatment options for early-stage patients.

News All Time

Insight the Future of Anti-Tau Drug Development for Alzheimer Disease Marco Meglio

Charles Bernick, MD, a staff neurologist at the Cleveland Clinic Lou Ruvo Center for Brain Health, commented on the scientific rationale, therapeutic strategies, and biomarker advances driving the next wave of anti-tau drug development in Alzheimer disease.

NeuroVoices: Christina Briscoe, MD, on Improving Timely and Effective Care for Infantile Epileptic Spasm Syndrome Marco Meglio

The pediatric epileptologist at Boston Children’s Hospital discussed national variability in treating infantile epileptic spasms syndrome and the evidence gaps that continue to shape clinical decision making.

FDA Approves New Intrathecal Administration Route for Spinal Muscular Atrophy Gene Therapy Marco Meglio

The FDA has approved Novartis’ intrathecal formulation of onasemnogene abeparvovec-brve, marketed as Itvisma, for patients ages 2 years and older living with spinal muscular atrophy.

Natalizumab Biosimilar Officially Launched in the United States Marco Meglio

Natalizumab-sztn is an FDA-approved monotherapy for all indications of the reference product natalizumab, including relapsing forms of multiple sclerosis and Crohn disease.

GLP-1 Semaglutide Fails to Outperform Placebo in Phase 3 EVOKE Trial of Alzheimer Disease Isabella Ciccone, MPH

Results from the EVOKE and EVOKE+ phase 3 studies reported that oral semaglutide did not significantly reduce clinical progression in patients with early symptomatic Alzheimer disease.

Study Identifies Environmental Risk Factors Significantly Associated With Neuromyelitis Optica Spectrum Disorder Isabella Ciccone, MPH

Findings revealed that vitamin D deficiency was associated with an increased risk of NMOSD in East Asian populations, whereas the effect of smoking among Caucasians and other populations was inconsistent.

Advancing DM1 and DMD Care: Insights on DYNE-101 and DYNE-251 Development Marco Meglio

Doug Kerr, MD, PhD, chief medical officer at Dyne Therapeutics, discusses the clinical development of DYNE-101 for myotonic dystrophy type 1 and DYNE-251 for Duchenne muscular dystrophy.

This Week on NeurologyLive® — November 24, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Positive Phase 3 OCEANIC-STROKE Data Position Asundexian for Upcoming FDA Submission Marco Meglio

Encouraging data from the OCEANIC-STROKE study suggest that asundexian may soon join the therapeutic landscape for secondary stroke prevention as Bayer advances toward submission.

Satralizumab Demonstrates Long-term Efficacy and Safety in Patients With NMOSD Louie Pasculli

A recent study confirms satralizumab's long-term safety and efficacy for treating neuromyelitis optica spectrum disorder, supporting its use as a maintenance therapy.

Case Report Suggests Progressive Brain Atrophy May Occur in NMOSD Without Relapse Marco Meglio

A case report reveals cognitive decline and brain atrophy in a patient with NMOSD, highlighting potential subclinical neurodegeneration despite limited relapses.

NeurologyLive® Friday 5 — November 21, 2025 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 21, 2025.

First Patient Dosed in Phase 2 Extension Study of Sabirnetug in Early Alzheimer Disease Louie Pasculli

Acumen Pharmaceuticals initiates a phase 2 trial extension for sabirnetug, targeting early Alzheimer disease and aiming for long-term safety insights.

NeurologyLive® Brain Games: November 23, 2025 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neural network plasticity after stroke!

Multi-Arm Phase 2 Trial Fails to Show Efficacy for Cognitive Programs in Treating Long COVID Marco Meglio

A recent trial reveals that online cognitive training and other interventions are ineffective for treating long COVID cognitive symptoms, highlighting treatment challenges.

Reimagining Neuroscience Trials: Precision, Partnership, and Progress Marco Meglio, Daniel Mikol, MD, PhD

Daniel Mikol, MD, PhD, vice president of neuroscience development at AbbVie, discussed how precision tools, AI, and patient partnership are reshaping the design and execution of modern neuroscience clinical trials.

Recommended News For You

These Athletes Weren't Doping. Their Genes Made It Look Like They Did.

Unlocking the secrets of the fibrotic fortress that surrounds and protects pancreatic cancer

A Win for Molecularly Guided Therapy for Cancer of Unknown Primary

automated, precise reporting for clonality testing using NGS.

Early cancer detection during pregnancy and the postpartum period may be aided by breast milk examination.

Spouses of Cancer Patients May Be at Increased Risk of Suicide

Base Treatment Decisions in Metastatic Breast Cancer on Presence of ESR1 Mutations

Recommended Articles For You

Precision to Personalization: Expanding Genetic Testing and Counseling in Oncology 

Exploring the Impact of Adrenal Myelolipoma on the Human Body 

Tremelimumab: A Potential Breakthrough in Cancer Treatment 

Breaking Down the Benefits and Risks of Hematopoietic Stem Cell Transplantation  

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Addition of regional nodal irradiation does not decrease rates of invasive breast cancer recurrence, study finds

2.

Increased anti-tumor response and reduced side effects from immune checkpoint inhibitors.

3.

UK study evaluates effectiveness of cancer diagnosis pathway for patients with non-specific symptoms

4.

New PET tracer enables same-day imaging of triple-negative breast and urothelial cancers

5.

First-Line Combination for Bladder Cancer Not Eligible for Cisplatin Just Misses Positive Outcome.

1.

Demystifying Hypereosinophilic Syndrome: Symptoms, Diagnosis, and Treatment Options 

2.

Can Wearables and AI Become a Gamechanger for Histiocytic Cancer Detection?

3.

Understanding Odontogenic Keratocyst: Symptoms, Causes, and Treatments from Dental Experts

4.

Unveiling the Mysteries of Smudge Cells: A New Frontier in Cellular Biology

5.

AI-Driven Chemotherapy: Transforming Cancer Care with Precision and Efficiency

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Navigating the Complexities of Ph Negative ALL - Part III

2.

Incidence of Lung Cancer- An Overview to Understand ALK Rearranged NSCLC

3.

Role of Nimotuzumab in Management of Nasopharyngeal Cancer

4.

Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in MRD Negativity

5.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot